Hanmi to invest $200 million to expand production into China

15 April 2016

South Korea-based pharmaceutical company Hanmi Pharmaceuticals (128940: KS) revealed that it has purchased roughly 200,000 square meters of land in the Yantai Economic and Technological Development Zone in China for about $10 million to construct the group’s new production base facilities for the Chinese and global markets.

Hanmi plans to invest $200 million until 2026 in the area to build facilities for the production of chemical and biologic drugs and health supplements, as well as a research and development center for new drug development.

“This investment should be perceived as a strategic decision for Hanmi to become a more globalized pharmaceutical company,” said a Hanmi official.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK